Literature DB >> 27540637

Risk Factors for Degree and Type of Sequelae After Involution of Untreated Hemangiomas of Infancy.

Eulalia Baselga1, Esther Roe1, Julien Coulie2, Fania Z Muñoz1, Laurence M Boon2, Catherine McCuaig3, Angela Hernandez-Martín4, Ignasi Gich5, Luis Puig1.   

Abstract

Importance: Infantile hemangiomas involute to some extent, but they often leave sequelae that may cause disfigurement. Factors determining the risk of permanent sequelae after regression are of crucial importance in treatment decision making.
Objectives: To describe the sequelae left by infantile hemangiomas after natural involution and to identify clinical characteristics that could predict the most severe or a particular type of sequelae. Design, Setting, and Participants: Multicentric retrospective cohort study of images from 187 infantile hemangiomas that had not received systemic treatment and had follow-up pictures until regression that were selected from photographic files taken between 2003 and 2013 at 4 university hospitals with large vascular clinics in 3 different countries. Main Outcomes and Measures: Outcome measures were the type of sequelae classified as residual telangiectasia, anetodermal skin, redundant skin, persistent superficial component, and the degree of sequelae ranging from 1 to 4.
Results: A total of 184 hemangiomas were included. The overall incidence of significant sequelae was 101 of 184 (54.9%). The most common sequelae after involution were telangiectasias (145, 84.3%), fibrofatty tissue (81, 47.1%), and anetodermic skin (56, 32.6%). The average age at which hemangioma completed involution was 3.5 years. Superficial and deep hemangiomas left significantly fewer sequelae than combined hemangiomas (Mann-Whitney; superficial vs deep, OR, 1.6; 95% CI, 0.6-3.8; P = .81; superficial vs combined, OR, 3.3; 95% CI, 1.7-6.3; P < .001; deep vs combined, OR, 2.1; 95% CI, 0.9-5.1; P < .001). Hemangiomas with a step or abrupt border of the superficial component left more severe sequelae than those with a smooth border (χ2,OR, 3.4; 95% CI, 1.8-6.6; P < .001). Superficial hemangiomas with a cobblestone appearance or rough surface left more severe sequelae than those with a smooth surface (Kruskal-Wallis; α, 0.05; P < .001). Using multivariate analysis, combined hemangiomas with a superficial component and a step border were associated with more sequelae. Conclusions and Relevance: In this retrospective study of sequelae in a large cohort of untreated infants, we quantified the prevalence of permanent scarring and identified clinical features predictive of permanent sequelae. Our observations provide useful information at a time when the treatment paradigm for hemangiomas has changed. Such knowledge may help primary care physicians predict the risk of sequelae and identify high-risk lesions to implement early treatment.

Entities:  

Mesh:

Year:  2016        PMID: 27540637     DOI: 10.1001/jamadermatol.2016.2905

Source DB:  PubMed          Journal:  JAMA Dermatol        ISSN: 2168-6068            Impact factor:   10.282


  10 in total

Review 1.  Medical Management of Infantile Hemangiomas: An Update.

Authors:  Caroline Colmant; Julie Powell
Journal:  Paediatr Drugs       Date:  2021-10-22       Impact factor: 3.022

2.  Maternal and Perinatal Risk Factors for Infantile Hemangioma: A Matched Case-Control Study with a Large Sample Size.

Authors:  Xue Gong; Tong Qiu; Liwei Feng; Kaiying Yang; Shiyi Dai; Jiangyuan Zhou; Xuepeng Zhang; Siyuan Chen; Yi Ji
Journal:  Dermatol Ther (Heidelb)       Date:  2022-06-25

Review 3.  Update on Treatment of Infantile Hemangiomas: What's New in the Last Five Years?

Authors:  Laura Macca; Domenica Altavilla; Luca Di Bartolomeo; Natasha Irrera; Francesco Borgia; Federica Li Pomi; Federico Vaccaro; Violetta Squadrito; Francesco Squadrito; Mario Vaccaro
Journal:  Front Pharmacol       Date:  2022-05-26       Impact factor: 5.988

Review 4.  Neonatal vascular anomalies manifesting as soft-tissue masses.

Authors:  Nadeen Abu Ata; Adrienne M Hammill; Arnold C Merrow
Journal:  Pediatr Radiol       Date:  2021-08-10

Review 5.  Interventions for infantile haemangiomas of the skin.

Authors:  Monica Novoa; Eulalia Baselga; Sandra Beltran; Lucia Giraldo; Ali Shahbaz; Hector Pardo-Hernandez; Ingrid Arevalo-Rodriguez
Journal:  Cochrane Database Syst Rev       Date:  2018-04-18

6.  Topical Application of 0.5% Timolol Maleate Hydrogel for the Treatment of Superficial Infantile Hemangioma.

Authors:  Hai Wei Wu; Chao Liu; Xuan Wang; Ling Zhang; Weien Yuan; Jia Wei Zheng; Li Xin Su; Xin Dong Fan
Journal:  Front Oncol       Date:  2017-06-27       Impact factor: 6.244

7.  Sequelae After Involution of Superficial Infantile Hemangioma: Early Intervention with 595-nm Pulsed Laser Combined with 755-nm Long-Pulsed Alexandrite Laser versus Wait-and-See.

Authors:  Ji-Cong Jiang; Qin Xu; Shan Fang; Yu Gao; Wan-Wan Jin
Journal:  Clin Cosmet Investig Dermatol       Date:  2021-01-12

8.  Evaluation of Transdermal Transport and Concurrent Cutaneous Hydrolysis of Timolol Prodrug for the Treatment of Infantile Hemangiomas.

Authors:  Shih-Jen Chang; Huiyuan Wang; Jialin Chen; Qianyi Chen; Lei Chang; Yongzhuo Huang; Yajing Qiu; Xiaoxi Lin
Journal:  Pharmaceutics       Date:  2022-08-01       Impact factor: 6.525

9.  Severe hypoglycemia in propranolol treatment for infantile hemangiomas.

Authors:  Akira Morimoto; Michio Ozeki; Satoru Sasaki; Naoko Baba; Yoshihiro Kuwano; Tsuyoshi Kaneko
Journal:  Pediatr Int       Date:  2022-01       Impact factor: 1.617

Review 10.  Current perspectives on the optimal management of infantile hemangioma.

Authors:  Peter Grzesik; June K Wu
Journal:  Pediatric Health Med Ther       Date:  2017-12-06
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.